Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8485519 | Vaccine | 2018 | 10 Pages |
Abstract
Invasive meningococcal disease (IMD) caused by Neisseria meningitidis is a potentially devastating condition that can result in death and is associated with serious long-term sequelae in survivors. Vaccination is the preferred preventative strategy. Quadrivalent polysaccharide-based vaccines that protect against infection caused by meningococcal serogroups A, C, W, and Y are not effective against meningococcal serogroup B (MenB), which was responsible for approximately 60% and 35% of confirmed IMD cases in the European Union and the United States in 2016, respectively. A recombinant protein MenB vaccine (MenB-FHbp [bivalent rLP2086; Trumenba®]) has been approved for protection against MenB infection in persons 10-25â¯years of age in the United States and Canada and for individuals â¥10â¯years of age in the European Union and Australia. In these regions, MenB-FHbp is approved as a 2- or 3-dose primary vaccination schedule. This report will review the current evidence supporting administration of MenB-FHbp as a 2-dose primary vaccination schedule. Different contexts in which a 2- or 3-dose primary vaccination schedule might be preferred (eg, routine prospective vaccination vs outbreak control) are reviewed.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Johannes Beeslaar, Judith Absalon, Paul Balmer, Amit Srivastava, Roger Maansson, Laura J. York, John L. Perez,